Saturday, October 23, 2021
Advertisement

Radiopharmaceuticals: hot or not?

The radiopharmaceuticals sector is attracting interest from private equity and corporates alike, but what does it take to succeed in a sector where barriers...

Resetting the consultant dynamic

In the third and final part of our three-part series exploring the impact of the Covid-19 pandemic on the private healthcare market, Check4Cancer chief...

Healthcare real estate from the fringes to the core

Historically, healthcare has been a niche area of the real estate investment market in the UK but Tom Morgan, senior director, healthcare at CBRE,...

Healthcare real estate: safe as houses

Strong underlying demographic trends, assured government funding and returns that are outperforming other real estate sectors are driving institutional investors of all types to...

Solid foundations

Healthcare real estate may still be regarded as an alternative asset class but consistent and stable returns are attracting increased interest from across the...

Can pharma innovate like a tech giant?

When it comes to digital disruption in healthcare, oncology, perhaps more than any other specialty, is changing the most. Dr Michelle Tempest and Roma...

Breaking down barriers

For too long, PMIs and private healthcare providers have operated in silos, developing their own proprietary systems and avoiding collaboration. This has to change...

Resetting the provider/ insurer relationship

In the first of a three-part series exploring the impact of the Covid-19 pandemic on the private healthcare market, Check4Cancer chief medical officer Professor Gordon...

Talking therapy in the virtual space

Talking therapy is moving off the couch and into the virtual space and the independent sector is leading the way. Dr Michelle Tempest, partner...

The eyes have it

Dr Michelle Tempest and Patrick Bansch of bespoke health and social care strategy and investment consultancy Candesic get a close-up look of the private...